drugset / Trial / NCT04089865

Oral Versus Intravenous Tranexamic Acid

NCT04089865 ↗

Phase 4 Completed 400 enrolled Hospital for Special Surgery, New York
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this randomized clinical control trial is to determine whether oral TXA dosing in THA/TKA result in more blood loss and more transfusions compared to IV TXA dosing in patients undergoing THA/TKA under neuraxial anesthesia. The main questions it aims to answer are: Does oral TXA dosing in THA/TKA result in more blood loss compared to IV TXA dosing? Does oral TXA dosing in THA/TKA result in more transfusions compared to IV TXA dosing? Participants will be randomly assigned to either get the Oral TXA (1950mg) or the IV TXA (1g) on their day of surgery. Researchers will compare these groups to see if any differences emerged. 200 THA patients (100 Oral, 100 IV), 200 TKA patients (100 oral, 100 IV).

Timeline

Start
2019-09-17
Primary completion
2021-11-10
Completion
2021-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1 g Oral
Subject Tranexamic Acid Small molecule 1950 mg Oral

Indications

No indication recorded.